Document Detail


Management of intracranial fungal infections in patients with haematological malignancies.
MedLine Citation:
PMID:  16225648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The incidence of, and mortality associated with, invasive fungal infections remains far higher than hoped. As a consequence of the overall increase in the incidence of such infections over time, the incidence of central nervous system (CNS) fungal infections is also increasing and, despite improvements in diagnostic techniques and the introduction of novel antifungal agents, therapy for CNS infections is still associated with discouragingly poor results. In patients with haematological malignancies, opportunistic infections with Candida or Aspergillus remain the most common infections affecting the CNS; however, opportunistic infections with less well-known fungi are becoming more common and must be considered in the differential diagnosis. New techniques for the early diagnosis of invasive fungal infections are emerging. Pharmacologic options for treating invasive fungal infections have also improved during the past few years, with new drugs becoming available that have broader antifungal spectra and better safety profiles. Other novel treatment approaches, such as combination therapy, are also being explored. Early investigations have produced encouraging results; however, large, prospective studies involving many patients are necessary to validate the widespread use of these approaches. This review analyses the existing guidelines for treatment of CNS fungal infections and the literature available on the use of new drugs to generate sets of recommendations for treatment of these life-threatening infections in patients with haematological malignancies.
Authors:
Gloria Mattiuzzi; Francis J Giles
Related Documents :
9876818 - Therapy of candida infections: susceptibility testing, resistance, and therapeutic opti...
19169948 - Fatal trichoderma harzianum infection in a leukemic pediatric patient.
11827268 - Assessing risk factors for systemic fungal infections.
20949548 - Efficacy of fungicides with various modes of action in controlling the early stages of ...
20739748 - Fitness and freezing: vector biology and human health.
19647338 - Impact of organisation and management factors on infection control in hospitals: a scop...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  British journal of haematology     Volume:  131     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-17     Completed Date:  2006-01-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  287-300     Citation Subset:  IM    
Affiliation:
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. gmattiuz@mdanderson.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antifungal Agents / therapeutic use
Central Nervous System Fungal Infections / complications,  diagnosis,  drug therapy*
Hematologic Neoplasms / complications*
Humans
Opportunistic Infections / complications,  diagnosis,  drug therapy*
Chemical
Reg. No./Substance:
0/Antifungal Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transient bullous dermolysis of the newborn in three generations.
Next Document:  Update on the diagnosis and management of pulmonary embolism.